8-K: Vaccinex Announces Positive Phase 1b/2 Trial Results for Pepinemab in Alzheimer's Disease

Vaccinex reports positive results from its early-stage SIGNAL-AD clinical trial, showing pepinemab is well-tolerated and demonstrates a statistically significant increase in brain metabolic activity in patients with Mild Cognitive Impairment due to Alzheimer's Disease.

Summary

• Vaccinex announced positive results from its SIGNAL-AD clinical trial of pepinemab in Alzheimer's Disease (AD).
• The trial met its primary endpoint, demonstrating that pepinemab is well-tolerated by patients with AD.
• No serious treatment-emergent adverse events related to the treatment were reported.
• A key secondary endpoint showed a statistically significant increase in brain metabolic activity, as measured by FDG-PET signal, in the medial temporal cortex of patients with Mild Cognitive Impairment (MCI) due to AD (p=0.0297).
• This result is consistent with previous findings in a Phase 2 study of pepinemab in Huntington's disease (HD), suggesting a similar mechanism of action.
• The study involved 50 patients with MCI due to AD or early Alzheimer's dementia, who received either pepinemab (40 mg/kg) or a placebo every four weeks for 12 infusions.
• The company believes pepinemab may be most effective in patients with very early-stage symptoms, such as MCI, and is exploring late-stage development with a major pharmaceutical partner.

Sentiment

Score: 8

Explanation: The document presents positive clinical trial results with a clear focus on the potential of pepinemab. The language is optimistic and forward-looking, suggesting a positive outlook for the company and its drug candidate. The results are statistically significant and the company is actively exploring late-stage development with a major pharmaceutical partner.

Positives

• Pepinemab demonstrated a favorable safety profile in the SIGNAL-AD trial, with no serious treatment-related adverse events.
• The study showed a statistically significant increase in brain metabolic activity in patients with MCI due to AD, suggesting a potential disease-modifying effect.
• The results are consistent with previous findings in Huntington's disease, supporting the drug's mechanism of action.
• Pepinemab has shown good tolerability in multiple clinical trials with over 600 patients.
• The company is actively exploring late-stage development in AD with a major pharmaceutical partner.

Negatives

• The study was not sufficiently powered to detect cognitive effects or changes in some additional secondary endpoints with statistical significance.
• The study indicates that pepinemab may be most effective in patients with very early stage symptoms, e.g. Mild Cognitive Impairment (MCI) due to AD, but not subsequent dementia.

Risks

• The company is dependent on the success of pepinemab.
• There are risks associated with the execution, cost, and completion of clinical trials.
• Interim data may not be predictive of final results.
• Regulatory approval is not guaranteed.
• The company faces the risk of delisting from Nasdaq if it cannot maintain compliance with listing standards.

Future Outlook

Vaccinex is actively exploring the potential for continuing late-stage development in AD together with a major pharmaceutical partner. The company also believes pepinemab could be an important contributor to combination therapy in AD.

Management Comments

• The results of the SIGNAL-AD study demonstrate that pepinemab has a similar effect in Alzheimer's to those we previously described for a key outcome in Huntington's disease, preventing the characteristic disease-related decline of brain metabolic activity in a brain region known to be affected early in disease progression, said the Company's CEO, Maurice Zauderer, PhD.
• Our study indicates that pepinemab may be most effective in patients with very early stage symptoms, e.g. Mild Cognitive Impairment (MCI) due to AD, but not subsequent dementia, Dr. Zauderer added.
• This suggests that a promising treatment strategy would be to identify people with MCI as early as possible and to treat with pepinemab to keep them from progressing for as long as possible.

Industry Context

The positive results for pepinemab come at a time when there are concerns about the limitations of existing treatments for Alzheimer's, such as anti-A amyloid antibodies. This positions pepinemab as a potential alternative or complementary treatment, particularly for patients at high risk for adverse events related to other therapies.

Comparison to Industry Standards

• The results of the SIGNAL-AD trial are being compared to the results of other Alzheimer's treatments, such as Leqembi (Eisai and Biogen) and Kisunla (Eli Lilly), which are anti-A amyloid antibodies.
• Unlike these treatments, pepinemab targets astrocyte activation, a different mechanism of action, which may offer an alternative approach for patients.
• The company is also comparing the results to their previous Phase 2 study in Huntington's disease, which showed similar positive effects on brain metabolic activity, suggesting a consistent mechanism of action across different neurodegenerative diseases.
• The company believes that pepinemab may be most effective in patients with very early stage symptoms, e.g. Mild Cognitive Impairment (MCI) due to AD, but not subsequent dementia, which is a different approach to other treatments that are often used in later stages of the disease.

Stakeholder Impact

• Shareholders may react positively to the positive clinical trial results.
• Patients with MCI due to AD may benefit from a potential new treatment option.
• The company's employees may be motivated by the positive results and the potential for future growth.
• Potential pharmaceutical partners may be interested in collaborating with Vaccinex on late-stage development.

Next Steps

• Vaccinex is actively exploring the potential for continuing late-stage development in AD together with a major pharmaceutical partner.
• The company will continue to evaluate pepinemab in other clinical trials, including in oncology.

Key Dates

Keywords

pepinemab, Alzheimer's Disease, Mild Cognitive Impairment, SEMA4D, clinical trial, FDG-PET, neurodegenerative disease, Huntington's disease, brain metabolic activity, astrocyte activation